CMG Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
CMG Pharmaceutical Co., Ltd.'s Market Cap is ₩1105B. At end of 2025 it was ₩2752B. Ranked #1189 of 2,436 in KR market (top 49%), #625 of 1,649 on KOSDAQ (top 38%), #137 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 110.50B KRW | KR#1,189/2,436 Sec#137/234 |
| Revenue | 110.12B KRW | KR#1,344/2,436 Sec#84/234 |
| Net Income | -8.38B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 319.33B KRW | KR#984/2,436 Sec#64/234 |
| Net Assets | 201.72B KRW | KR#920/2,436 Sec#65/234 |
| Employees | 282 | KR#831/2,436 Sec#70/234 |
| Value | ||
| P/B | 0.55x | KR#874/2,436 Sec#40/234 |
| P/S | 1.00x | KR#1,390/2,436 Sec#82/234 |
| FCF Yield | -36.79% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -4.16% | KR#1,719/2,436 Sec#125/234 |
| ROA | -2.63% | KR#1,744/2,436 Sec#126/234 |
| Op. Margin | -4.80% | KR#1,853/2,436 Sec#125/234 |
| Revenue Growth | 23.71% | KR#578/2,436 Sec#55/234 |
| Earnings Growth | -473.96% | KR#1,624/2,436 Sec#108/234 |
| Financial Health | ||
| Debt Ratio | 58.30% | KR#200/2,436 Sec#27/234 |
| Total Debt | 88.05B KRW | KR#759/2,436 Sec#48/234 |
| FCF | -40.65B KRW | KR#2,054/2,436 Sec#203/234 |
| Cash | 9.18B KRW | KR#1,718/2,436 Sec#139/234 |
| Current Ratio | 1.25x | KR#1,526/2,436 Sec#161/234 |
| Performance | ||
| 1Y Return | -61.11% | KR#2,251/2,436 Sec#213/234 |
| 1M Return | -20.81% | KR#2,213/2,436 Sec#213/234 |
| From 52W High | -66.17% | KR#1,997/2,436 Sec#170/234 |
| 1Y MDD | -67.52% | KR#1,820/2,436 Sec#154/234 |
| Trading | ||
| Volume | 675,729 shares | KR#135/2,436 Sec#9/234 |
| Foreign Own. | 7.18% | KR#611/2,436 Sec#57/234 |
| Per Share | ||
| EPS | -57 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,364 KRW | KR#2,196/2,436 Sec#196/234 |
Company Info
CMG Pharmaceutical, established in 2001, merged Celltrate Pharm Korea in 2008 and now primarily focuses on the research, development, production, and sales of pharmaceuticals and health functional foods. The company applies oral disintegrating films, leveraging its core STARFILM Technology, to incrementally modified drugs and is expanding its product portfolio into new business sectors like anti-cancer drugs, anti-aging, and ophthalmology. CMG Pharmaceutical is actively pursuing revenue growth and market share expansion through new drug development, facilitated by US FDA product approvals and technology exports. The company is headquartered in Gangnam-gu, Seoul.